• Something wrong with this record ?

Impact of Pseudomonas aeruginosa carriage on intensive care unit-acquired pneumonia: a European multicentre prospective cohort study

C. Recanatini, CH. van Werkhoven, TE. van der Schalk, F. Paling, D. Hazard, L. Timbermont, G. Torrens, A. DiGiandomenico, MT. Esser, M. Wolkewitz, F. Sifakis, H. Goossens, M. Bonten, A. Oliver, S. Malhotra-Kumar, J. Kluytmans, ASPIRE-ICU Study Team

. 2025 ; 31 (3) : 433-440. [pub] 20241110

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc25009751

OBJECTIVES: Pseudomonas aeruginosa (PA) is a common causative pathogen of pneumonia acquired in the intensive care unit (ICU). The aim of this study was to determine the incidence of PA ICU pneumonia (PAIP) and to quantify its independent association with PA colonization at different body sites. METHODS: Adult patients on mechanical ventilation at ICU admission were prospectively enrolled across 30 European ICUs. PA colonization in the perianal area and in the lower respiratory tract was assessed within 72 hours after ICU admission and twice weekly until ICU discharge. PAIP development was evaluated daily. Competing risk models with colonization as a time-varying exposure and ICU death and discharge as competing events were fitted and adjusted for confounders to investigate the association between PA carriage and PAIP. RESULTS: A total of 1971 subjects were enrolled. The colonization prevalence with PA in the first 72 hours of ICU admission was 10.4% (179 perianal and 51 respiratory), whereas the acquisition incidence during the ICU stay was 7.0% (158 perianal and 47 respiratory). Of the 43 (1.8%) patients who developed PAIP, 11 (25.6%) were PA colonized on admission and 9 (20.9%) acquired colonization before PAIP onset. Both perianal (adjusted subdistribution hazard ratio, 4.4; 95% CI, 1.7-11.6) and respiratory colonization (adjusted subdistribution hazard ratio: 4.6, 95% CI, 1.9-11.1) were independently associated with PAIP development. DISCUSSION: PAIP incidence was higher in PA colonized vs. non-colonized patients. Colonization of both the rectum and of the respiratory tract was associated with development of PAIP. The increased risk of PA colonization for subsequent infection provides an opportunity for targeted preventive interventions.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009751
003      
CZ-PrNML
005      
20250429134543.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cmi.2024.11.007 $2 doi
035    __
$a (PubMed)39532190
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Recanatini, C $u Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: claudia.recanatini@gmail.com
245    10
$a Impact of Pseudomonas aeruginosa carriage on intensive care unit-acquired pneumonia: a European multicentre prospective cohort study / $c C. Recanatini, CH. van Werkhoven, TE. van der Schalk, F. Paling, D. Hazard, L. Timbermont, G. Torrens, A. DiGiandomenico, MT. Esser, M. Wolkewitz, F. Sifakis, H. Goossens, M. Bonten, A. Oliver, S. Malhotra-Kumar, J. Kluytmans, ASPIRE-ICU Study Team
520    9_
$a OBJECTIVES: Pseudomonas aeruginosa (PA) is a common causative pathogen of pneumonia acquired in the intensive care unit (ICU). The aim of this study was to determine the incidence of PA ICU pneumonia (PAIP) and to quantify its independent association with PA colonization at different body sites. METHODS: Adult patients on mechanical ventilation at ICU admission were prospectively enrolled across 30 European ICUs. PA colonization in the perianal area and in the lower respiratory tract was assessed within 72 hours after ICU admission and twice weekly until ICU discharge. PAIP development was evaluated daily. Competing risk models with colonization as a time-varying exposure and ICU death and discharge as competing events were fitted and adjusted for confounders to investigate the association between PA carriage and PAIP. RESULTS: A total of 1971 subjects were enrolled. The colonization prevalence with PA in the first 72 hours of ICU admission was 10.4% (179 perianal and 51 respiratory), whereas the acquisition incidence during the ICU stay was 7.0% (158 perianal and 47 respiratory). Of the 43 (1.8%) patients who developed PAIP, 11 (25.6%) were PA colonized on admission and 9 (20.9%) acquired colonization before PAIP onset. Both perianal (adjusted subdistribution hazard ratio, 4.4; 95% CI, 1.7-11.6) and respiratory colonization (adjusted subdistribution hazard ratio: 4.6, 95% CI, 1.9-11.1) were independently associated with PAIP development. DISCUSSION: PAIP incidence was higher in PA colonized vs. non-colonized patients. Colonization of both the rectum and of the respiratory tract was associated with development of PAIP. The increased risk of PA colonization for subsequent infection provides an opportunity for targeted preventive interventions.
650    _2
$a lidé $7 D006801
650    12
$a Pseudomonas aeruginosa $x izolace a purifikace $7 D011550
650    12
$a jednotky intenzivní péče $x statistika a číselné údaje $7 D007362
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a prospektivní studie $7 D011446
650    _2
$a lidé středního věku $7 D008875
650    12
$a pseudomonádové infekce $x epidemiologie $x mikrobiologie $7 D011552
650    _2
$a senioři $7 D000368
650    _2
$a incidence $7 D015994
650    _2
$a přenašečství $x epidemiologie $x mikrobiologie $7 D002353
650    _2
$a prevalence $7 D015995
650    _2
$a infekce spojené se zdravotní péčí $x epidemiologie $x mikrobiologie $7 D003428
650    _2
$a dospělí $7 D000328
650    _2
$a ventilátorová pneumonie $x epidemiologie $x mikrobiologie $7 D053717
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a van Werkhoven, C H $u Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
700    1_
$a van der Schalk, T E $u Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
700    1_
$a Paling, F $u Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
700    1_
$a Hazard, D $u Institute for Medical Biometry and Statistics, University Medical Centre Freiburg, Freiburg, Germany
700    1_
$a Timbermont, L $u Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
700    1_
$a Torrens, G $u Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Centro de Investigación Biomédica en Red - Enfermedades Infecciosas (CIBERINFEC), Palma de Mallorca, Spain
700    1_
$a DiGiandomenico, A $u Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
700    1_
$a Esser, M T $u Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
700    1_
$a Wolkewitz, M $u Institute for Medical Biometry and Statistics, University Medical Centre Freiburg, Freiburg, Germany
700    1_
$a Sifakis, F $u AstraZeneca PLC, Department of US Medical Affairs, Gaithersburg, MD, USA; Department of Real-World Evidence, Gilead Sciences, Foster City, CA, USA
700    1_
$a Goossens, H $u Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
700    1_
$a Bonten, M $u Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; European Clinical Research Alliance on Infectious Diseases, Utrecht, the Netherlands
700    1_
$a Oliver, A $u Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Centro de Investigación Biomédica en Red - Enfermedades Infecciosas (CIBERINFEC), Palma de Mallorca, Spain
700    1_
$a Malhotra-Kumar, S $u Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
700    1_
$a Kluytmans, J $u Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
710    2_
$a ASPIRE-ICU Study Team
773    0_
$w MED00001139 $t Clinical microbiology and infection $x 1469-0691 $g Roč. 31, č. 3 (2025), s. 433-440
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39532190 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134538 $b ABA008
999    __
$a ok $b bmc $g 2311243 $s 1246832
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 31 $c 3 $d 433-440 $e 20241110 $i 1469-0691 $m Clinical microbiology and infection $n Clin Microbiol Infect $x MED00001139
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options